(Bloomberg) -- Adtalem Global Education Inc. shares are slumping Tuesday after Safkhet Capital Management LLC said it’s betting against the for-profit education company. Most Read from Bloomberg Musk Says First Neuralink Patient Received Implant in Brain Traders Line Up for ‘Once-in-a-Generation’ Emerging Markets Bet UPS to Cut 12,000 Jobs, Bring Workers in Five Days a Week Blackstone Is Building a $25 Billion Empire of Power-Hungry Data Centers Trump Cash Stockpile at Risk From $450 Million Dual Verdicts It’s the latest call from the hedge fund, founded by short seller Fahmi Quadir, who made a prescient 2015 bet against the drugmaker formerly called Valeant Pharmaceuticals near its peak. The firm also made a winning call against shares of Wirecard AG, the German payment operator that crumbled in 2020 amid allegations of fraud. “After our extensive research, including interviews with former executives and students, we believe the business model is simple: fast and loose admissions made possible by aggressive and sometimes deceptive tactics,” Safkhet Capital wrote in a post Tuesday on social media platform X, announcing the short report. Read more: Why Activist Short Sellers Stir Up Controversy: QuickTake Adtalem Global, which is based in Illinois, didn’t respond to an email and phone calls requesting comment. Shares of the company, the parent organization of schools including the American University of the Caribbean School of Medicine and the Ross University School of Veterinary Medicine, fell as much as 20% Tuesday. Read more: Short Seller Who Foresaw Valeant Crash Bets on Tesla Drop The stock had surged more than 50% in the year through Monday’s close, when the firm had a market capitalization of about $2.3 billion. It reached an all-time high above $70 per share in 2010. The company has three buy ratings, no holds, no sells and an average 12-month price target of $65, implying a return of about 11% from Monday’s closing level, data compiled by Bloomberg show (Updates shares.) Most Read from Bloomberg Businessweek There’s So Much Data Even Spies Are Struggling to Find Secrets Basketball, Basketball, Basketball: Inside Steve Ballmer’s New $2 Billion Arena How a Lucky Break Fueled Eli Lilly’s $600 Billion Weight-Loss Empire How to Handle the Dreaded Political Shop Talk at Work AI Needs So Much Power That Old Coal Plants Are Sticking Around ©2024 Bloomberg L.P.
Short Seller Who Targeted Valeant Takes Aim at College Owner
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...